Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Formulary decisions and health economics
Autore:
Glazer, WM;
Indirizzi:
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA Harvard Univ Boston MA USA 02115 Gen Hosp, Sch Med, Boston, MA 02115 USA
Titolo Testata:
JOURNAL OF CLINICAL PSYCHIATRY
, volume: 59, anno: 1998, supplemento:, 19
pagine: 23 - 29
SICI:
0160-6689(1998)59:<23:FDAHE>2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
QUALITY-OF-LIFE; NEUROLEPTIC-RESISTANT SCHIZOPHRENIA; CLOZAPINE; SCALE; HALOPERIDOL; REDUCTION; DISORDERS; COST;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Clinical Medicine
Citazioni:
31
Recensione:
Indirizzi per estratti:
Indirizzo: Glazer, WM POB 121,Beach Plum Lane, Menemsha, MA 02552 USA POB 121,Beach Plum Lane Menemsha MA USA 02552 ha, MA 02552 USA
Citazione:
W.M. Glazer, "Formulary decisions and health economics", J CLIN PSY, 59, 1998, pp. 23-29

Abstract

Because of increasing concerns about health care costs, physicians must consider the cost-effectiveness of a treatment strategy, as well as its efficacy and safety. The question of whether the greater expense of a newer drugis justified over the cost of a generic drug deserves a comprehensive evaluation. The determination of effectiveness and tolerability of the newer antipsychotics should be expanded to include quality-of-life issues, reintegration of the patient into the community, resource utilization, and medical costs. There are clear indications that patients who take atypical antipsychotics utilize fewer medical resources than patients who take typical antipsychotics; however, the positive outcomes of the newer drugs must be translated into cost benefits if formularies are to be intelligently controlled.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 18:40:18